SCPS:OTC-Scopus Biopharma Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.0021

Change

0.00 (0.00)%

Market Cap

USD 0.05M

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

N/A

USD 649.39B
CMXHF CSL Limited

N/A

USD 94.38B
CSLLY CSL Ltd

N/A

USD 92.66B
UCBJF UCB SA

N/A

USD 28.35B
UCBJY UCB SA ADR

N/A

USD 27.94B
ARGNF argenx SE

N/A

USD 23.04B
GNMSF Genmab A/S

N/A

USD 16.66B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 6.87B
REGMF RemeGen Co. Ltd

N/A

USD 6.81B
IVBIY IVBIY

N/A

USD 6.79B

ETFs Containing SCPS

IEO 18.24 % 0.42 %

N/A

N/A
NRGO 10.00 % 0.00 %

N/A

N/A
NRGZ 10.00 % 0.00 %

N/A

N/A
YGRN 10.00 % 0.00 %

N/A

N/A
FRAK 8.73 % 0.54 %

N/A

N/A
XLE Energy Select Sector SPDR.. 8.29 % 0.13 %

N/A

USD 36.53B
FTXN First Trust Nasdaq Oil & .. 7.51 % 0.60 %

N/A

USD 0.21B
JHME 6.90 % 0.48 %

N/A

N/A
OILD MicroSectorsTM Oil & Gas .. 6.84 % 1.24 %

N/A

USD 0.02B
VDE Vanguard Energy Index Fun.. 6.76 % 0.10 %

N/A

USD 8.34B
NXF:CA First Asset Energy Giants.. 6.62 % 0.72 %

N/A

CAD 0.15B
OILU MicroSectorsTM Oil & Gas .. 6.46 % 1.22 %

N/A

USD 0.05B
DIG ProShares Ultra Oil & Gas 6.23 % 0.95 %

N/A

USD 0.10B
DDG 5.83 % 0.95 %

N/A

N/A
ERYY 4.79 % 0.45 %

N/A

N/A
HUL-U:CA 4.46 % 0.00 %

N/A

N/A
HUL:CA 4.46 % 2.20 %

N/A

N/A
GASX 4.29 % 1.01 %

N/A

N/A
SXLE:LSE SPDR S&P U.S. Energy Sele.. 4.27 % 0.00 %

N/A

USD 0.94B
NANR SPDR S&P® North American.. 4.09 % 0.35 %

N/A

USD 0.53B
GASL 1.45 % 1.19 %

N/A

N/A
TERM 0.88 % 0.64 %

N/A

N/A
VVL:CA Vanguard Global Value Fac.. 0.65 % 0.40 %

N/A

CAD 0.35B
JIGB JPMorgan Corporate Bond R.. 0.39 % 0.14 %

N/A

USD 0.05B
SCHJ Schwab 1-5 Year Corporate.. 0.09 % 0.00 %

N/A

USD 0.41B
BWX SPDR® Bloomberg Internat.. 0.00 % 0.50 %

N/A

USD 0.86B
EBND SPDR® Bloomberg Emerging.. 0.00 % 0.41 %

N/A

USD 1.91B
MTUM 0.00 % 0.15 %

N/A

N/A
QUAL 0.00 % 0.15 %

N/A

N/A
TGED:CA TD Active Global Enhanced.. 0.00 % 0.00 %

N/A

CAD 0.27B
RYE 0.00 % 0.40 %

N/A

N/A
WIP SPDR® FTSE International.. 0.00 % 0.50 %

N/A

USD 0.39B
HPF:CA Energy Leaders Plus Incom.. 0.00 % 1.74 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -95.12% 5% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -95.12% 5% F 1% F
Trailing 12 Months  
Capital Gain -95.96% 8% B- 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -95.96% 8% B- 4% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -63.09% 1% F N/A F
Dividend Return -63.09% 1% F N/A F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 41.11% 71% C- 57% F
Risk Adjusted Return -153.48% 2% F 1% F
Market Capitalization 0.05M 15% F 9% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.